Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine.

NCT00263679 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

321

Enrollment

INDUSTRY

Sponsor class

Conditions

Acellular Pertussis
Diphtheria
Tetanus

Interventions

BIOLOGICAL: Prophylaxis: Diphtheria, tetanus and pertussis

Sponsor

GlaxoSmithKline